Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.71 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.71 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | AKT1 | P31749 | 9/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.38 |
| ▸ | PRKACA | P17612 | 5/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 4/20 | 0.37 |
| ▸ | CLK2 | P49760 | 3/20 | 0.37 |
| ▸ | PRKX | P51817 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168879 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4HTR2AAKT1CHRNB4 | |
| SCHEMBL2170794 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4HTR2AAKT1CHRNB4 | |
| SCHEMBL2170244 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4HTR2AAKT1CHRNB4 | |
| SCHEMBL2169514 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4HTR2AAKT1CHRNB4 | |
| SCHEMBL621422 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4HTR2AAKT1CHRNB4 | |
| SCHEMBL2168872 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4HTR2AAKT1CHRNB4 | |
| SCHEMBL621421 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4HTR2AAKT1CHRNB4 | |
| SCHEMBL4247313 | 0.87 | CHRNB2 (0.66) | CHRNB2CHRNA4AKT1CHRNB4CHRNA3 | |
| SCHEMBL1691835 | 0.87 | CHRNB2 (0.66) | CHRNB2CHRNA4AKT1CHRNB4CHRNA3 | |
| SCHEMBL14138470 | 0.87 | CHRNB2 (0.72) | CHRNB2CHRNA4AKT1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011144192-A | COMPOUND CAPABLE OF ACTIVATING CHOLINERGIC RECEPTOR | TARGACEPT INC | 2011-07-28 | — | — | JP | disclosed |
| US-20110130428-A1 | Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130428-A1 | Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| WO-2010080757-A2 | COMBINATIONS WITH AN ALPHA-4BETA-2 NICOTINIC AGONIST | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009151394-A1 | SUBLINGUAL COMPOSITIONS COMPRISING (2S) - (4E) -N-METHYL-5- (3- (5-ISOPROPOXYPYRIDIN) YL) -4-PENTEN-2-AMINE | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130428-A1 | Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine | NT5C3B, HTR3C, HTR3E | CHRNB2 294/4885CHRNA4 293/4885HTR2A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.